Addition of Chidamide to the Combination Treatment of Decitabine Plus Camrelizumab in Combination Treatment Resistant/Relapsed Patients With Classical Hodgkin Lymphoma

  • STATUS
    Recruiting
  • End date
    Feb 25, 2026
  • participants needed
    100
  • sponsor
    Chinese PLA General Hospital
Updated on 24 February 2022
lymphoma
cell transplantation
classical hodgkin lymphoma
refractory hodgkin lymphoma

Summary

This is a Phase II clinical trial for Decitabine plus Camrelizumab resistant/relapsed patients with Hodgkin Lymphoma. The purpose is to evaluate the efficacy and safety of the combination therapy of Chidamide plus Decitabine Plus Camrelizumab.

Details
Condition Hodgkin Lymphoma
Treatment Decitabine, Chidamide, Camrelizumab
Clinical Study IdentifierNCT04233294
SponsorChinese PLA General Hospital
Last Modified on24 February 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Subjects must have histological confirmation of relapsed or refractory Hodgkin lymphoma (HL)
12 to 75 years of age
ECOG performance of less than 2
Life expectancy of at least 3 months
Subjects with lymphoma must have at least one measureable lesion >1 cm as defined by lymphoma response criteria
Subjects must be relapsed or resistant for the treatment of Decitabine plus Camrelizumab. Subjects with autologous hematopoietic stem-cell transplantation are eligible which must be more than 3 months
Subjects must have adequate marrow, live, renal and heart functions

Exclusion Criteria

Subjects with any autoimmune disease or history of syndrome that requires corticosteroids or immunosuppressive medications
Serious uncontrolled medical disorders or active infections, pulmonary infection especially
Active alimentary tract hemorrhage or history of alimentary tract hemorrhage in one month
Prior organ allograft
Women who are pregnant or breastfeeding
Women with a positive pregnancy test on enrollment or prior to investigational product administration
Subjects who are compulsorily detained for treatment of either a psychiatric or physical (eg, infectious disease) illness
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note